Crossmark

3549 Continuous ofatumumab treatment up to 7 years shows a consistent safety profile and delays disability progression in people with RMS

Crossref DOI link: https://doi.org/10.1136/bmjno-2025-ANZAN.102

Published Online: 2025-10-23

Published Print: 2025-10

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Pardo, Gabriel

Bar-Or, Amit

Montalban, Xavier

Nakahara, Jin

Morrow, Sarah A

Bhatt, Alit

Wu, Min

Pearce, Gregory L

Sullivan, Roseanne

Abeyewickreme, Anil

Seze, Jerome de

Wiendl, Heinz

Hauser, Stephen L

Parratt, John
License Information

License valid from 2025-10-22